Incorporating valuable microbiome data into drug development pipeline
16 Feb 2022
A three-phase project will build a ‘Microbiome Atlas’ to power an algorithm for predicting the microbiome’s effect on the mechanisms of drugs in the body. This atlas will map out the bi-directional relationship between a drug and the microbiome, enabling us to identify patterns in drug behaviour. Findings could speed up the advancement of new, precision medicines and treatments.
The newly launched collaborative project is being run under the umbrella of the Pistoia Alliance and funded by alliance members: Bayer, BMS, Eagle Genomics, Pfizer, Roche and Takeda. The "pre-competitive microbiome and drug metabolism project" aims to gather all existing microbiome data to create a global standardised ‘atlas’ that scientists can refer to when choosing new drug candidates.
The microbiome has a profound impact on drug behaviour in an individual, and if the industry is going to improve the efficacy of drugs and develop the field of precision medicine, then a greater understanding is needed of an individual’s microbiome and how it interacts with medicines. However, the information on the microbiome is vast and hard to make sense of – there are currently 5,000 different known species of microbes in the body. The database developed by the cross-industry collaboration in this project will collate and develop scientific understanding, by mapping the bi-directional relationship between the metabolic effect of drugs and dietary supplements on the microbiome, as well as the microbiome’s influence on the efficacy of these drugs and dietary supplements.
“The microbiome is now a widely accepted modulator of health, disease and therapeutic response, but it is not currently being utilised to its full potential. Gathering and standardising the vast amounts of data on the microbiome-derived metabolism is the first step towards being able to predict the relationship between the body’s metabolism and new drug candidates,” comments Dr Manuela Pausan, Microbiota researcher at Bayer. “It is vital that organisations come together at this early stage so that we embed good practices and universal standards that will benefit all future research topics in the field. Collaborating on data in this way will allow new trends to be uncovered, and potentially revolutionise how the industry approaches creating new treatments.”
The project will be conducted in three stages:
Stage One: Curate existing data on the microbiome-derived metabolism of pharmaceutical drugs and other chemical compounds (such as polyphenols, flavonoids, alkaloids) from existing publications, public data repositories and internal pharma company data. Then, standardise this data to build a machine-readable ‘atlas’, that will allow researchers to quickly search and discover the links between the microbiome, the body and other chemicals.
Stage Two: Determine any specific chemical groups of interest, which will be decided together with the companies that are financially supporting the project, and start building a prediction tool that can be incorporated into future therapeutic development.
Stage Three: Scale the predictive algorithm and aim to make this database the standard one for determining the effect of drugs and dietary supplements on the microbiome.
“The Eagle Genomics team is delighted to participate in this pre-competitive microbiome and drug metabolism project as members of the Pistoia Alliance,” commented Dr Sven Sewitz, Director of Biodata Innovation, Eagle Genomics. “Scientists are beginning to understand the complex interactions between gut microbes, their metabolism, and their effect on drug efficacy. We are keen to work alongside other members of the project team to develop the computational tools and data infrastructure that will enable and accelerate this exciting work. Science and innovation in this field are moving at an incredible pace, and the outcomes of this project will be shared with a wide group so advances can be applied in many contexts. We are at the beginning of a new phase in drug development, which will be of great benefit to patients all over the globe.”
“This project will truly enable companies to take microbiome data from being an area of academic research to actually being applicable to the drug discovery process, with demonstratable outcomes. We recognise that the microbiome is an important area to our members, and we need to enable them to explore it further. This project will help members bring the next frontier of R&D into the real world,” comments Dr Imran Haq, Emerging Science and Technology Strategic Lead at the Pistoia Alliance. “This is what the Pistoia Alliance is all about – providing a powerful forum for organisations to collaborate on ideas and deliver tangible results that will drive the future of healthcare.”
The Pistoia Alliance is inviting any interested members to come forward to get involved with the project. For more information, please email ProjectInquiry@pistoiaalliance.org.